A major change in U.S. prostate cancer screening guidance
On November 12, 2026, the American Cancer Society released an updated guideline for the early detection of prostate cancer, its first major update on this topic since 2010.
The previous ACS guideline emphasized discussion between average-risk men and their clinicians about whether to undergo prostate-specific antigen testing. The new guideline directly recommends regular PSA-based screening for men who meet age and health criteria, while continuing to require that patients understand potential benefits, limitations and harms before screening begins.
Average-risk men: every two years from age 50 through 69
For men who are not in a higher-risk group and are expected to live at least another ten years, ACS recommends beginning PSA blood testing at age 50 and screening every two years through age 69.
PSA is a protein produced by both normal and abnormal prostate cells. An elevated level can be associated with prostate cancer, but it can also result from benign prostate enlargement, inflammation, recent medical procedures or temporary factors. PSA is therefore a screening and risk-assessment tool, not a stand-alone diagnosis of prostate cancer.
Who is advised to start at age 45
ACS recommends annual PSA screening from age 45 through 69 for Black men and for non-Black men with a strong family history of prostate cancer. A strong family history includes a father, brother or son diagnosed before age 65, or multiple first-degree relatives diagnosed at any age.
For non-Black men with one first-degree relative diagnosed at age 65 or older, the guideline recommends screening every two years from age 45 through 69. Family history involves not only whether a relative had prostate cancer, but also the age at diagnosis and the number of close relatives affected.
Screening after age 70 requires individualized decisions
For men ages 70 to 74, ACS recommends an individualized decision based on previous PSA results, overall health, life expectancy and patient preferences because the balance of benefits and harms remains uncertain.
Routine screening is generally not recommended after age 75, although exceptionally healthy men ages 75 to 79 with a rising PSA may choose to discuss continued testing. Screening is not recommended for men age 80 or older or for men of any age who are not expected to live another ten years because of other health conditions.
An elevated PSA should not immediately mean cancer or biopsy
The guideline recommends repeating a PSA test within two weeks to three months when the level is 3.0 ng/mL or higher for men ages 45 to 69, or 6.5 ng/mL or higher for men ages 70 to 74, rather than moving directly from one elevated result to biopsy.
If the elevation is confirmed, patients should be offered prostate MRI and/or a validated biomarker test to help guide the biopsy decision. This risk-stratified approach aims to identify clinically significant cancers while reducing invasive procedures prompted by temporary PSA elevations or low-risk findings.
Why PSA screening has been controversial
Prostate cancers vary widely in behavior. Some grow rapidly and metastasize, while others progress so slowly that they may never cause symptoms or threaten a patient's life.
Widespread PSA screening can detect more early cancers, but it can also produce false positives, overdiagnosis and treatment of tumors unlikely to cause harm. Biopsy can involve bleeding, infection and anxiety, while surgery or radiation can affect urinary, sexual and bowel function. The goal is not to find the greatest possible number of tumors, but to identify life-threatening cancer early enough to improve outcomes.
Active surveillance helps reduce overtreatment
For prostate cancer assessed as having a low risk of growth or spread, the updated guideline recommends that active surveillance be offered as the initial management option. Surveillance may include scheduled PSA testing, imaging, repeat biopsy or other assessment, with treatment considered if risk increases.
Active surveillance is not the same as ignoring cancer or simply waiting. It is a structured follow-up strategy intended to help some patients delay or avoid treatment-related effects while preserving the opportunity to intervene if the disease changes.
This is a U.S. guideline, not a universal screening standard
Recommendations differ among countries and professional organizations because they consider disease burden, health-system capacity, evidence and the practical delivery of screening programs. The UK National Screening Committee, for example, does not currently recommend population screening for average-risk men and supports targeted screening only for a defined group of men with a pathogenic BRCA2 variant and relevant family history.
International patients should identify who issued a guideline, the country and population it addresses, and when it was updated. An individual screening decision should also consider age, racial background, family history, genetic risk, previous PSA results, other medical conditions and life expectancy.
This article summarizes American Cancer Society and other public professional information about an international medical guideline update. It does not provide cancer screening, diagnostic or individualized medical advice. Decisions to begin, continue or stop PSA screening should be discussed with qualified professionals familiar with the patient's health.